BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Schiff, MD
ABTC/University of Virginia
Study Chair - Ranjit Bindra, MD
ABTC/Yale University
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uab Comprehensive Cancer Center
Birmingham, Alabama, United States
- University of California, Los Angeles
Los Angeles, California, United States
- Yale University
New Haven, Connecticut, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, United States
- Washington University
St Louis, Missouri, United States
- Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
- Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
- University of Virginia
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Feb 2020
- Primary completion
- 31 Oct 2023
- Completion
- 31 Oct 2023
- Last update posted
- 14 Jan 2025
- Registered enrollment
- 67
- Registry id
- NCT03914742
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.